tbuckley/cabot-search huggingface dataset:
Impact of the recurrence score (RS) result and mismatch repair status (MMR) on agreement between oncologists (MDs) for stage II colon cancer (CC) recurrence risk (RR) assessment: A novel clinical utility endpoint for prognostic markers.
Authors: Robin Katie Kelley, Margarita Lopatin, Jimmy Hwang, Michael Crager, Adrienne A Brenner, Jane Kuczma, Ashley King, Calvin Chao, Mark Lee, Alan Paul Venook
Journal: Journal of Clinical Oncology (2013)

349 Background: Appropriate use of prognostic and predictive markers depends on quality of evidence for clinical utility in addition to clinical validity. In stage 2 CC, RR assessment is based traditionally on clinicopathologic factors (CP) with limited clinical validation and varies substantially across providers. We hypothesized that the validated Oncotype DX Colon Cancer RS and MMR tests may impact clinical decision-making by decreasing variation in RR assessment across MDs. We conducted a survey to compare the level of MD agreement on stage 2 CC RR assessment using CP alone vs CP+RS+MMR (CP+). Methods: A clinical trial database was randomly sampled for 100 cases of stage 2 CC stratified on T-stage, MMR and RS groups. Anonymous internet surveys asked each MD to assess 3-year RR for 10 cases with CP and 10 different cases with CP+. MDs were divided into panels of 5; all members of each panel reviewed the same cases. Agreement in RR among MDs was assessed using within-panel mean squared difference in RR assessments and analyzed using generalized linear models. Results: 30 community (C) and 20 university-based (U) MDs (Assoc of Northern California Oncologists or NCCN, respectively) completed evaluable surveys April-June 2012. For C vs U, median years in practice were 5 and 2; prior use of RS 13% vs 25%; and routine MMR use 21% vs 55%. The standard deviation of the differences (SDD) in RR assessments for CP alone was high overall (7%), and greater for U vs C MDs (8.2% vs 6.4%). CP+ produced higher agreement in RR assessments vs CP for both C (p&lt;.001) and U (p=0.04) MDs, with 23% and 20% proportional reduction in SDD. ForT3 MMR-proficient (P) patients (n=70), CP+ produced higher agreement in RR for both C (p&lt;0.001) and U (p=0.01) MDs with 37% and 29% reduction in SDD. Conclusions: Addition of RS+MMR to CP significantly increased MD agreement on RR assessment in stage 2 CC, including T3 MMR-P patients. Agreement was higher among C than U MDs. MD agreement on stage 2 CC RR assessment and Tx decision-making warrants consideration as a novel endpoint for clinical utility of RS, MMR, and other prognostic markers.
Pediatric Acute Myeloid Leukemia with t(8;16)(p11;p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Münster AML Study Group.
Authors: Eva A Coenen, C. Michel Zwaan, Christine J Harrison, Oskar A. Haas, Valerie de Haas, V Mihal, Barbara De Moerloose, M Jeison, Jeffrey Rubnitz, Daisuke Tomizawa, Donna Johnston, Todd A. Alonzo, Henrik Hasle, Dirk Reinhardt, Anne Auvrignon, Michael Dworzak, Andrea Pession, Vincent H.J. van der Velden, John Swansbury, Kit Fai Wong, Kiminori Terui, Sureyya Savasan, M Winstanley, G Vaitkeviciene, Martin Zimmermann, Rob Pieters, Marry M. van den Heuvel-Eibrink
Journal: Blood (2012)
Editorial Board
Authors: Treasa Creavin, Sara Cullinan, Feng Chen, Ellie Carr, Suado Nur, Lara Crow, Mat Mccutcheon, Philip Patenall, Neill Sharp, K Anderson, P Borst, C Epstein, G Fink, W Gehring, Switzerland Guarente, S Henikoff, J Hodgkin, H Horvitz, E Koonin, E Meyerowitz, S Moreno, D Sherratt, J Smith, M Takeichi, Japan Kobe, Davide Rambaldi, Federico Giorgi, Fabrizio Capuani, Andrea Ciliberto, Francesca Ciccarelli, Robert Harvey, Maya Topf, Kirsten Harvey, Mark Li, Robert Weinberg, Robin Ricke, Janine Van Ree, Jan Van Deursen, Sascha Feuerhahn, Jean-Marc Egly, Praveen Sethupathy, Francis Collins, Anna Kloc, Robert Martienssen, Lianne Krab, Susan Goorden, Ype Elgersma, Dan Arking, Aravinda Chakravarti, Charles David, Suat Özbek, Patrizia Adamczyk, Sebastian Meier, Barbara Pauly, Jarrod Chapman, Jung Hwang, Takashi Gojobori, Thomas Holstein Opinion
Journal: Trends in Genetics (2008)
PLoS Medicine Issue Image | Vol. 3(10) October 2006
Journal: PLoS Medicine (2006)

The cover image takes its theme from Dorothy Porter's article, which looks at the historical roots of social medicine and asks where it is heading. The article is part of a special collection of eleven magazine pieces and five original research papers examining social and cultural aspects of medicine and health and the socioeconomic determinants of disease. Image Credit: Cover design by Natalie Davis, Public Library of Science, with images from the US Library of Congress (an image used by Dorothy Porter in her article) and Tavis Ford
EXCEPTIONAL MEN AND HIGHER STANDARDS OF MEDICAL EDUCATION
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NAVAL SURGEONS VOLUNTEERING FOR MILITARY HOSPITAL DUTY.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Trade Pamphlets.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prospective study of α-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma
Authors: H Oka
Journal: Hepatology (1994)

The usefulness of measurements of serum α-fetoprotein elevation for diagnosis of the development of hepatocellular carcinoma was evaluated by a prospective study of 260 patients with cirrhosis. Hepatocellular carcinoma was found in 55 patients during the 5-yr follow-up, excluding 7 found to have hepatocellular carcinoma in the first 6 mo. The cumulative incidence of hepatocellular carcinoma was 26 in the 185 patients who had α-fetoprotein levels below 20 ng/ml at the time of entry and 46 in the 68 patients who had α-fetoprotein levels of 20 ng/ml or more but below 200 ng/ml. In 169 of the patients, serum levels of α-fetoprotein were assayed regularly for at least 2 yr. The incidence of hepatocellular carcinoma development in the 36 patients who had repeated transient increases in α-fetoprotein to above 100 ng/ml was 36. This was significantly higher than the incidence in the 99 patients who had α-fetoprotein levels consistently below 20 ng/ml. Thus patients who had α-fetoprotein levels of 20 ng/ml or more, who had transient increases in α-fetoprotein or who had both should be treated as being in a super-high-risk group for hepatocellular carcinoma. Frequent and careful examination by ultrasonography of such patients is recommended. (Hepatology 1994;19:61–66).
The relationship of postoperative delirium with psychoactive medications
Authors: E. R. Marcantonio
Journal: JAMA (1994)

<h3>Objective.</h3> —To examine the role of medications with known psychoactive properties in the development of postoperative delirium. <h3>Design.</h3> —Nested case-control study within a prospective cohort study. <h3>Setting.</h3> —General surgery, orthopedic surgery, and gynecology services at Brigham and Women's Hospital, Boston, Mass. <h3>Patients.</h3> —Cases (n=91) were patients enrolled in a prospective cohort study who developed delirium during postoperative days 2 through 5. One or two controls (n=154) were matched to each case by the calculated preoperative risk for delirium using a predictive model developed and validated in the prospective cohort study. <h3>Main Outcome Measures.</h3> —Medication exposures were ascertained from the medical record by a reviewer blinded to the study hypothesis. Exposures to narcotics, benzodiazepines, and anticholinergics were recorded for the 24-hour period before delirium developed in the 91 cases and for the same 24-hour postoperative period for the 154 matched controls. <h3>Results.</h3> —Delirium was significantly associated with postoperative exposure to meperidine (odds ratio [OR], 2.7; 95% confidence interval [CI], 1.3 to 5.5) and to benzodiazepines (OR, 3.0; 95% CI, 1.3 to 6.8). Meperidine had similar associations with delirium whether administered via epidural or patient-controlled routes, although only the epidural route reached significance (OR, 2.4; 95% CI, 1.3 to 4.4; OR, 2.1; 95% CI, 0.4 to 10.7, respectively). For benzodiazepines, long-acting agents had a trend toward stronger association with delirium than did short-acting agents (OR, 5.4; 95% CI, 1.0 to 29.2; vs 2.6; 1.1 to 6.5), and high-dose exposures had a trend toward slightly stronger association than low-dose exposures (OR, 3.3; 95% CI, 1.0 to 11.0; vs 2.6; 0.8 to 9.1). Neither narcotics (OR, 1.4; 95% CI, 0.5 to 4.3) nor anticholinergic drugs (OR, 1.5; 95% CI, 0.6 to 3.4) were significantly associated with delirium as a class, although statistical power was limited because of the high use of narcotics and the low use of anticholinergics in the study population. <h3>Conclusions.</h3> —Clinicians caring for patients at risk for delirium should carefully evaluate the need for meperidine and benzodiazepines in the postoperative period and consider alternative therapies whenever possible. (<i>JAMA</i>. 1994;272:1518-1522)
Updated Hodgkin's disease. A. Introduction
Authors: P. Rubin
Journal: JAMA (1972)

A number of major strides have been made during the past decade toward the cure of Hodgkin's disease. They include the following: (1) development of a meaningful classification (Introductory Fig); (2) a greater effort to determine the true extent of the disease by means of sophisticated radiography; (3) the use of laparotomy; (4) biopsy evaluation of inaccessible abdominal sites; (5) the development of very refined megavoltage radiation therapy techniques; and (6) an effective, cyclic, multidrug, chemotherapy schedule. As a result, an air of optimism has supplanted the pessimism that pervaded the literature and clinical practice in the past. These aggressive diagnostic and therapeutic approaches have overcome the initial obstacles to cure. A new medical radicalism has been spawned by the combination of all types of contemporary technology; success has resulted from multidisciplinary teamwork leading into interdisciplinary decision making. The concern now is that promising investigational procedures and new ideas presently
JOHN HAYGARTH (1740-1827)— EPIDEMIOLOGIST AND RHEUMATOLOGIST
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Actinomycosis of pericardium
Authors: K. Mohan
Journal: JAMA (1974)

ACTINOMYCOSIS is a progressive granulomatous disease with focal or systemic manifestations characterized by a tendency to produce multiple draining sinuses.<sup>1</sup>It is an uncommon infection, involving the heart in less than 2% of reported cases.<sup>2</sup>Heart disease is usually secondary to extension of primary thoracic actinomycosis. When the heart is involved, 42% of the patients have cardiac symptoms, with congestive heart failure predominating.<sup>3</sup>We present a case of actinomycotic purulent pericarditis and congestive heart failure in which the patient required pericardiectomy for restoration of normal cardiac function. <h3>Report of a Case</h3> A 51-year-old white woman was admitted with shortness of breath of two days' duration. She gave a history of low-grade temperature for the past two weeks and cough, nausea, and vomiting for the past four days. She was never hospitalized before except for tonsillectomy in early childhood. The patient was acutely ill, with shortness of breath;
GOLDING BIRD (1814-1854)— CLINICAL CHEMIST OF GUY'S
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the Editor
Authors: Susan E. Bates
Journal: Clinical Cancer Research (2006)

“Predictive Preclinical Models of Human Cancer: Mouse Models Get Another Chance” is devoted to the use of mouse models in cancer. Guest Editor Dr. Cory Abate-Shen has put together a collection of reviews by outstanding investigators who describe the new generation of mouse models designed to study human cancer and the potential impact of these models on identifying new treatments for patients with cancer.Murine models have been used for decades for testing new cancer therapies, but there is a widespread perception that xenograft models lack adequate predictive power for the clinic. Some investigators have turned their attention to genetically engineered mouse models of cancer, and it is this latter strategy that is the subject of this issue of CCR Focus. The expression of oncogenes, the deletion of tumor suppressor genes, or a combination of the two approaches can be achieved through genetic modification of mice. Many of these models replicate familial cancer syndromes in humans. As such, they are superior models for testing drugs for prevention of cancer, while still limited in their ability to replicate the stepwise and stochastic nature of mutations acquired during carcinogenesis. A new generation of genetic models attempts to come ever closer to replicating human carcinogenesis, including the elusive metastatic phenotype. Six articles address these issues: Abate-Shen in the overview, Olive and Tuveson on mouse models of pancreatic cancer, Fomechencko and Holland on models of brain tumors, Carver and Pandolfi on models of leukemia and prostate cancer, Degenhardt and White on models with defined molecular pathways, and Singh and Johnson with the industry point of view.CCR Focus offers these reviews to educate the interested non-expert and stimulate interest and encouragement and inspiration for those labouring in the field.
Drugs Can Be Dangerous in Early Pregnancy, OB Warns
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The effect of cigarette smoking on hemoglobin levels and anemia screening
Authors: D. Nordenberg
Journal: JAMA (1990)

The relationships among cigarette smoking, hemoglobin concentration, and carboxyhemoglobin concentration were examined using data from the Second National Health and Nutrition Examination Survey. Among women, smokers had a mean (±SE) hemoglobin level of 137 ±0.4 g/L, significantly higher than the mean hemoglobin level of 133 ±0.5 g/L for never-smokers. Among men, the mean hemoglobin levels for smokers and never-smokers were 156 ±0.4 and 152 ±0.5 g/L, respectively. No significant difference in mean hemoglobin was noted between ex-smokers and never-smokers. Mean hemoglobin levels and carboxyhemoglobin levels increased progressively with the number of cigarettes consumed per day. Cigarette smoking seems to cause a generalized upward shift of the hemoglobin distribution curve, which reduces the utility of hemoglobin level to detect anemia. Among women of comparable socioeconomic status, the prevalence of anemia was 4.8% ±0.6% among smokers, compared with 8.5% ± 1.2% among never-smokers. This study suggests that minimum hemoglobin cutoff values should be adjusted for smokers to compensate for the masking effect of smoking on the detection of anemia. (<i>JAMA</i>. 1990;264:1556-1559)
A Study of the Human Heart as a Multiple Dipole Electrical Source
Authors: JOHN H. HOLT, ANTHONY C. L. BARNARD, M. STUART LYNN
Journal: Circulation (1969)

Using the method previously described, the time-varying strengths of 12 dipoles (representing the depolarization of the ventricles) were calculated from body surface potential measurements. Dipole activities (DA) were obtained for each dipole by time integration of its strength. Seventy-two patients with angiographically determined left ventricular muscle weight (LVMW) were studied. Fifty-two of 53 patients with increased LVMW had increased DA in the left ventricle and septum (LVSDA). Thus, diagnostic sensitivity was 98%. Sixteen of 19 patients with normal LVMW had normal LVSDA (specificity, 84%). The correlation between LVSDA and LVMW was r 2 =86%, and the standard error of the LVMW estimate ( see ) was±49 g. A subgroup with pure left ventricular hypertrophy (LVH) consisting of 27 patients over 25 years of age with isolated aortic valve disease was studied separately. The correlation between LVSDA and LVMW was r 2 =92% and see was ±31 g. After correcting for the uncertainty in the angiographic LVMW measurements, the see for the complete group was reduced to ±37 g. The diagnosis and quantitation of LVH with this method was considerably better than with conventional electrocardiography or vectorcardiography.